Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
As per the agreement, NSE-listed Vaishali Pharma Limited will take over the entire domestic and international marketing of Jark Pharma’s portfolio of quality based ayurvedic products
The project will generate and supply green energy to fulfill about 50% present consumption of the company
Ipca Laboratories now holds 58.88% of the paid-up equity share capital of the company.
The product is backed by required scientific proof and comparative bioequivalence studies
Post the sale, Patel family has become the single largest promoter shareholder in the company
CINRYZE is plasma-derived C1-I NH approved for routine prevention (prophylaxis), short-term prevention or pre-procedure prevention, and acute attacks of HAE.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
Subscribe To Our Newsletter & Stay Updated